|
Company* (Country; Symbol) |
Company* (Country; Symbol) |
Type/Product Area | Terms/Details (Date) |
| Apotex Inc.* (Canada) | Intas Bio-pharmaceuticals Ltd.* (India) | Collaboration to develop a biosimilar protein for neutropenia | Kwizda Pharma, of Austria, agreed to transfer all of its rights to G-CSF to Apotex in Europe, and Intas agreed to extend Apotex's rights to include North America (5/2) |
| BioMS Medical Corp. (Canada; TSX:MS) | Orcrist Bio Inc.* | Royalty and assignment agreement for HYC750, a technology based on hya-luronic acid being developed to treat side effects of chemotherapy | BioMS terminated its license with the University of Alberta, which transferred the license to Orcrist; BioMS will receive certain milestone payments in addition to a royalty on net sales (5/9) |
| BioSeek Inc.* | Lexicon Pharmaceuticals Inc. (LXRX) | Research collaboration to use BioSeek's BioMAP Systems to further evaluate selected compounds associated with several of Lexicon's drug discovery programs | Financial terms were not disclosed (4/29) |
| Brain AG* (Germany) | BioSilta Oy* (Finland) | Collaboration to co-develop microwell plate-based high-cell density protein expression and high-throughput enzyme discovery technologies using the cell culture technology platform EnBase | Brain will receive access to the EnBase technology, and BioSilta will receive access to application-relevant process developments on high-throughput enzyme discovery and protein expression (4/28) |
| Caliper Life Sciences Inc. (CALP) | DiscoveRx Corp.* | Collaboration that enables functional cell-based G protein-coupled receptor assays from DiscoveRx to be performed on Caliper's LabChip platforms | The combined offering bundles Caliper LabChip systems with DiscoveRx's cellular assays to help researchers more efficiently discover GPCR drugs (5/5) |
| Champions Biotechnology Inc. (OTC BB: CSBR) | ImClone Systems Inc. (IMCL) | Agreement for the preclinial evaluation of certain therapeutic antibodies in ImClone's clinical development pipeline | ImClone will use Champions' Biomerk Tumorgrafts in the initial preclinical evaluation (5/7) |
| ChemDiv Inc.* | Syndexa Pharmaceuticals Corp.* | Collaborative discovery research agreement, under which ChemDiv will discover small-molecule ligands for biotargets nominated by Syndexa | Financial terms were not disclosed (4/28) |
| CreaGen Biosciences Inc.* | ProXyChem LLC* | Agreement to combine their expertise, which includes structure-based drug design and lead optimization services to the biotech and pharmaceutical industries | Terms of the agreements were not disclosed (5/9) |
| Crucell NV (the Netherlands; CRXL) | Toyobo Gene Analysis Co. Ltd. (Japan; FSE:TO7) | Nonexclusive STAR research license agreement | The goal is to evaluate the STAR technology for generating cell lines for the production of recombinant proteins for third-party customers; financial terms were not disclosed (4/29) |
| Cytopia Ltd. (Australia; ASX: CYT) | Cancer Therapeutics CRC Pty Ltd. (OTC BB:CTHP) | Cancer drug discovery and development collaboration leveraging Cytopia's early stage drug discovery pipeline of kinase inhibitors | Cytopia will retain an option over exclusive commercialization rights for any drug candidates delivered by the collaboration; if all milestones are achieved, the companies will share revenues, as well as royalty payments from any marketed drugs (5/8) |
| DiaKine Therapeutics Inc.* | Kinexum Metabolics Inc.* | Agreement to jointly develop a new combination therapy that has shown in preclinical studies to cause Type I diabetes to go into remission by protecting and promoting the growth of new insulin-producing cells | A Phase II trial with the new therapy, consisting of DiaKine's Lisofylline and Kinexum's INGAP peptide, is expected to begin in late 2008 (5/6) |
| Dyax Corp. (DYAX) | Cubist Pharmaceuticals Inc. (CBST) | Licensing agreement for North American and European rights to the intravenous formulation of DX-88 for use in preventing blood loss during surgery | The deal is worth $231.5M, which includes $15M in cash up front, plus an additional $2.5M in milestones in 2008, as well as $214M more in clinical, regulatory and sales milestones; it also entails tiered, double-digit royalties based on DX-88 sales by Cubist (4/24) |
| Geron Corp. (GERN) | Stemcell Technologies Inc.* | License agreement related to primate pluripotent stem cells, including human embryonic stem cells | The nonexclusive license includes rights under certain Geron patents to develop, manufacture and sell cell culture media and matrix surfaces for research use only; Geron will receive license payments and is entitled to royalties (5/15) |
| GTC Biothera-peutics Inc. (GTCB) | LFB Biotechnologies* (unit of French firm LFB SA) | Agreement to include GTC's recombinant human alpha-1 antitrypsin program in its strategic collaboration for the development of selected recombinant plasma proteins and monoclonal antibodies | LFB will provide additional funding to support GTC's work for 2008 (5/8) |
| Illumina Inc. (ILMN) | Genpathway Inc.* | Partnership to provide researchers whole-genome chromatin immuno-precipitation sequencing services | Final data analysis is completed by Genpathway (4/30) |
| ImaRx Therapeutics Inc. (IMRX) | Microbix Biosystems (Canada; TSX:MBX) | Agreement for Microbix to acquire urokinase inventory and related assets | Microbix bought urokinase for $12M up front plus an additional $5M upon achievement of an inventory stability milestone (5/7) |
| ImmuneRegen BioSciences Inc. (subsidiary of IR BioSciences Holdings Inc.; OTC BB:IRBO) | BioCure Inc.* | Agreement to design and develop a wound- healing product | BioCure will use ImmuneRegen's Homspera to create a combination product composed of the potential wound-healing therapeutic and BioCure's GelSpray (4/24) |
| Novozymes Biopharma UK Ltd. (UK; LSE:NVZ) | Dyax Corp. (DYAX) | Nonexclusive license agreement for albufuse and Novozymes yeast-based expression platform | Dyax gains nonexclusive rights to develop albumin fusions of Kunitz domain proteins and antibody fragments for therapeutic and diagnostic applications (5/15) |
| OncoMethylome Sciences (Belgium; BR:ONCOB) | Laboratory Corp. of America (NYSE:LH) | Exclusive license on technology to perform commercial MGMT methylation laboratory testing services in the U.S. and Canada subject to limited exceptions | OncoMethylome qualifies for an up-front fee, milestone payments and royalties from LabCorp (4/22) |
| PDC Biotech GmbH* (Austria) | Theratechnologies (Canada; TSX:TH) | Exclusive license agreement for Theratechnologies' family of antagonists of the prostaglandin F2 alpha receptor for use in preterm labor and primary dysmenorrhea | Financial terms were not disclosed (5/12) |
| Promega Corp.* | GeneCopoeia* | Agreement to pair Promega's HaloTag protein fusion technology with GeneCopoeia's human and mouse open reading frame OmicsLink sequences | The alliance allows the companies to provide a set of tagged expression-ready ORF clones that can be employed in proteomics and other research (4/22) |
| Qiagen NV (the Netherlands; QGEN) | Geneart AG (Germany; PK:GNRTF) | Collaboration to develop, produce and commercialize a product line for the enhanced production of all 35,000 human proteins | Financial terms were not disclosed (5/14) |
| Scil Technology GmbH* (Germany) | Medtronic Inc. (NYSE:MDT) | Development, licensing and supply agreement for joint development of Scil's biologic dental regenerative materials for use in dental implant bone restoration and treatment of periodontal disease | Scil will handle research and development, while Medtronic takes care of clinical trials, regulatory approvals and commercialization (4/29) |
| VaxGen Inc. (OTC BB:VXGN) | Emergent BioSolutions Inc. (NYSE:EBS) | Agreement to sell VaxGen's next generation anthrax vaccine candidate and related technology | The deal is worth $2M up front, and up to $8M more in milestone payments, plus percentages of future net sales (5/5) |
| Vybion Inc.* | Meridian Bioscience Inc. (VIVO) | Letter of intent for Vybion to sell its recombinant protein business to Meridian | Vybion would receive both cash and future royalties based on sales of the applicable products (5/14) |
|
Notes: * Private companies are indicated with an asterisk; ** Denotes the date the item ran in BioWorld International. Unless otherwise notes, the trading symbols listed for public biotechnology companies are on the Nasdaq market.ASX = Australian Stock Exchange; BR = Brussels Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; TSX = Toronto Stock Exchange. | |||
